CIS PharmaOpportunity Contact
Christoph Schäfer, CEO
Bubendorf, Switzerland
Switzerland
CIS Pharma Website
TherapeuticRegistered Pharmalicensing.com

The Cefuroxime Application System is CIS Pharma’s patented drug/device combination for preparation and injection of cefuroxime intracameral antibiotic to prevent Endophthalmitis.

Introduction/Background
Every year, 20 million cataract patients receive an intraocular lens. Endophthalmitis, also called intravitreal infection, is a rare but severe inflammatory condition of the eye, caused by microbial contamination during the surgical procedure. The incidence is reported between 0.1% and 0.05% without intracameral antibiotic prophylaxis. The treatment of Endophthalmitis is expensive and one out of two patients lose sight or the eye. 


Description of Technology
The drug/device combination includes an innovative vial adaptor that prevents the 10mg/ml cefuroxime sodium solution from particulate contamination, containing several 5-micron filters. After reconstitution of the cefuroxime powder, the vial adaptor separates into two parts, immediately offering the surgeon an injection syringe with his cannula of choice. The second part of the adaptor closes the cefuroxime vial and prevents multi-use of the overfill contained. 

Advantages
CIS Pharma’s Cefuroxime Application System simplifies the preparation and injection of 1mg/0.1ml cefuroxime and reduces the main risk of the procedure, being dilution errors associated with non-standardized compounding. In summary, the drug/device combination improves the safety of the treatment: without the drug/device combination, the compounding is bearing the risk of contamination, dilution errors and wrong choice of diluent, as reported.

Clinical Trials
The product is approved based on a decentralized procedure in all major European markets. The injection of intracameral cefuroxime with or without the use of perioperative topical antibiotics 
reduces the risk by a factor 5 to 6 for postoperative endophthalmitis following cataract surgery as shown in a number of studies across Europe and USA.

Type of Business Relationship Sought
Out license, Partnership

Patent Information
WO2012110057

COGNIS GROUP MISSION
The pace of change in our world continues to accelerate.  We all see this play out on the grand stage daily:  new diseases, warming oceans, increased hurricanes and fires, supply shortages, changes in social behaviors, more focus on alternative energies; the list goes on and on.  
We all have a role in proactively preparing for the ongoing shifts that we will encounter.  Our passionate team at Cognis Group is focused on helping you navigate innovation potential for the greatest collective benefits to people, the planet, and long term profits.

For more information, contact us:
info@cognisgroup.com
US: +1 303 709 3157
UK: +44 1904 435190